latest news releases from the newsroom
Cauley Bowman Carney & Williams, PLLC
Cauley Geller Bowman & Coates, LLP Announces NCI Building Systems, Inc. Investors have Until June 18th to File Lead Plaintiff Motion -- NCS
LITTLE ROCK, Ark., June 15, 2001 (PRIMEZONE) -- The deadline for purchasers of NCI Building Systems, Inc. ("NCI" or the "Company") (NYSE:NCS) securities to move for lead plaintiff in a securities fraud class action recently brought against the Company is rapidly approaching. If you purchased NCI securities between February 23, 2000 and April 12, 2001, inclusive (the "Class Period"), and you wish to be a lead plaintiff in the case, you must move to serve as lead plaintiff by filing a motion in the United States District Court for the Southern District of Texas, Houston Division by June 18, 2001. A copy of the complaint filed in this action is available from the Court, or can be viewed on the firm's Website at http://www.classlawyer.com/pr/NCI_Building.pdf.
Signature Eyewear Reports Second Quarter Operating Results
INGLEWOOD, Calif., June 15, 2001 (PRIMEZONE) -- Signature Eyewear (OTCBB:SEYE) today reported results for its second fiscal quarter and six-month period ended April 30, 2001, reflecting profitability for the second consecutive quarter and significant improvements in operations, based on an aggressive cost-reducing turnaround program.
Northrop Grumman Corp.
Northrop Grumman Confirms Financial Guidance
LOS ANGELES, June 15, 2001 (PRIMEZONE) -- Northrop Grumman Corporation (NYSE:NOC) announced today that it will conduct a series of meetings with institutional investors in Europe in mid-June which will include discussions of future expectations. The company stated that during those meetings it intends to confirm the financial guidance given with its first quarter earnings release on April 23, 2001.
Donner Corp. International
FDA Grants Fast Track Status to CytRx Corp.'s FLOCOR Product for the Treatment of Acute Chest Syndrome in Patients with Sickle Cell Disease
SANTA ANA, Calif., June 15, 2001 (PRIMEZONE) -- Donner Corp. International, a broker/dealer headquartered in Santa Ana, CA., today issued a Morning Call Note on CytRx Corp., Norcross, Georgia (Nasdaq:CYTR). CytRx is a biotechnology company with a DNA delivery technology currently being used by Merck & Co. in Merck's HIV vaccine R&D program and a phase III product, FLOCOR(tm), under development for the treatment of sickle cell disease patients suffering from vaso-occlusive crisis.